Announcements Trials
Browse Landscape

Status

Recruiting 755Active not recruiting 461Completed 292Not yet recruiting 199Terminated 129Enrolling by invitation 15Suspended 10Withdrawn 8Available 7No longer available 4Approved for marketing 2Temporarily not available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Recurrence 3Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 2Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1HER2-positive Breast Cancer 1Glioma 1EGFRm Advanced Non-Small Cell Lung Cancer 1Cholangiocarcinoma 1Carcinoma, Basal Cell 1Advanced Cancers and FGFR Genetic Alterations 1

Interventions

cemiplimab 1amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × Carcinoma, Non-Small-Cell Lung × 1 year × Clear all
NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Approved for marketing
DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT04599712 2025-06-13

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Janssen Research & Development, LLC

Approved for marketing
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡